Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PUR003 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| placebo | PLACEBO_COMPARATOR | normal saline for inhalation |
| PUR003 | ACTIVE_COMPARATOR | PUR003 for inhalation |
| Name | Type | Description |
|---|---|---|
| PUR003 | DRUG | PUR003 for inhalation |
| Placebo | DRUG | Normal saline for inhalation |
Inclusion Criteria: 1. Signed written informed consent. 2. Ability and willingness to return to the outpatient clinic for repeated clinic visits and complete all assessments. 3. Adult male or female subject, 18-60 years of age. 4. Stable, mild asthma not requiring any medical treatment other than s...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
PUR003 is an investigational small molecule developed by Pulmatrix, Inc. for asthma. It has been studied in a single Phase 1 clinical trial that has been completed. PUR003 is not approved for any indication and remains in clinical development.
PUR003 is being developed for the treatment of asthma. The only clinical trial of PUR003 enrolled participants with asthma and related lung and bronchial diseases. It is an investigational therapy and has not been approved for commercial use.
PUR003 is developed by Pulmatrix, Inc., a biopharmaceutical company whose common stock trades under the ticker symbol PULM. Pulmatrix is the sponsor of the clinical program evaluating PUR003 in asthma.
PUR003 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The program remains investigational and has not advanced beyond early-stage testing.
PUR003 has been evaluated in one completed Phase 1 trial, NCT00989521, titled Effect of PUR003 on Asthma. The trial enrolled 7 participants in Canada, was randomized, double-blind, and placebo-controlled, and included adults 18 years and older of all sexes.
No, PUR003 is not FDA approved. It is an investigational small molecule that has completed a single Phase 1 clinical trial for asthma. Approval would require successful results in later-stage clinical development, which has not been reported.